Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If i can remember correctly, blazed was all right...I could be wrong. ????
Bashers are back at RB
Usually a good sign!
AX I got out a week or so ago, bought more mfys.
ride it out if u can, better than losing I think?
I just bought 2900 just because I didn't want to see it in the 30's. lol, I'm pretty sure I was the last trade.
Holiday here in Canada, markets closed!!
oledudes, how come your not assistant anymore, and verylong how come you are??????
Still around, have you been in contact with this company? Im 40 cents post split so ill be around for a while untill i get back to break even. good luck i think we will need it
For the SEC to move fast like that means that you werent the only one to complain, which is good, that way you or someone else will get a quick response...good job
There was more news 4pm friday, I didn't see anything posted on it and figured nobody seen it. Just a revision of the olympus deal.
Im off to Mexico for a week in a couple of hours, hopefully when I get back S#%T will hit the fan ( in a good way). Lot of people dumping money back in
While you guys are drinking the good stuff I'll be there drinking their kifey booze, but after a few it all tastes the same, have fun next week it will be good. (gut feeling)
Hopefully they have a computer in the room so I can check in.
Adios amigos
AXCLR, if he does post here he can't be very busy with the company, and thats not good....
I wonder who it is?????????????????
I read somewhere its under 10....%75 sure
So I bought in today 1.80, so will the split show tomorrow or Monday morning???
I hope they go for a nice run like mfys did after the split, that's basically why I got in, this thing is acting the same way mfys did.
Did anybody get in to bluechips new company? What was the ticker?
By the way has anybody talked to him lately?
Boys, Give it time, if axclr or whatever the f@#k his name is right then July 4th they will take care of it all, the company is not going to move any faster just cause u want it to.
You all say your LONG in MFYS....well if you are then relax and be LONG...
By the way I'm drunk as a skunk but still think I'm right!!!!
This CANADIAN booze is soooooooo good
Bigheadd
My sell is at $30 lol, I wonder how long I'll have to wait
After the best news we've got so far, ie, numbers, trying to get on another exchange and more money to come, the volume is 30000, what gives??????
?????????????
At 3:01 theres a sale at 1.725
At 3:54 theres a sale .98
Is that a mistake or what
Dwudman, I've read it...probably 10 times,I think I know what your talking about...please give a hint so I know we are on the same page.
Predictions for the coming week???
Would like yours too bluechip.
Medify Solutions (OTC:MFYS)
Medify Solutions Receives $3.90 Short Term Target Price
Today’s Top Story Zurich
STRONG BUY ON
Medify Inc. (MFYS.pk)
May 27th, 2005
Symbol: MFYS (MFYS.PK) 3 Months High / Low: $1.17 / $0.39
TTS Zurich 12 Months Price Target: $3.90
Recent Price: $1.04 Potential 12 Months Upside: 274%
Shares O/S: 80,656,000 Consensus Price Target (www.stocktargets.com): $3.32
Free Float: 22,276,000 Average Daily Shares Traded: 3’164’000
Summary
- The company opens the door to a brand new 430’000’000 US$ market
- The company gets approved for the first e-learning system for all NHS professionals
- TTS Zurich’s target price for Medify is $3.90, consensus stock price target today is at $3.32
- Its partnership with Oracle on the e-learning strengthens its future
- The stock price is low by comparison to peers and needs to be discovered
Company Description
A few months ago, Medify Solutions Inc. (MFYS.pk) was the first UK business to have developed a Secure Remote Access product, addressing critical requirements of the UK National Health Service, bringing the latest flexible integrated wireless and web-based technologies. That product was MedifyRemote. Today, Medify has introduced a brand new product, its E-Learning product. The content of the product are medical educational programs organized in modules for each and every healthcare professional of the NHS to utilize. Medifiy has created, compiled and copyrighted this product. Its modules are accessible remotely through the Web, through an SPV or smartphone or any other mean linking a user to the database. This application becomes highly lucrative, given that every GP in the NHS has an obligation to follow 30 hours per annum of accredited training, which then has to be validated and proven. Medify has integrated all these elements into its modules. From a competition point of view, nobody is in sight yet. Medify is the only partner to Oracle and Oracle is meant to host all e-learning applications for the NHS. This doesn’t exclude any competition, but signals that Medify is ahead of the competitors. Not only is Medify’s E-Learning product supposed to be quite lucrative, it is also a great addition to the existing product line.
Stock Chart
Medify Solutions Inc’s stock has been trading since March 1st, 2005 with an average of 1’944’000 shares per day. After the initial euphoria on the stock as it got listed for the first time, MFYS.pk has stabilized and the stock is ready for long term trend to the forecast target. This timing should be taken advantage of TTS Zurich’s stock price target is 3.89 US$ as detailed in the following pages and this target should be achieved within a 12 to 18 months horizon.
Industry Analysis
An Industry Comparables Analysis (ICA) has been performed on Medify Solutions Inc. The medical supplies industry is quite broad and perhaps the best comparative to the Company, as it is the closest industry it would fit in. The major players in the sector with an equivalent market capitalization as Medify Solutions Inc. are tabulated here below. A few elements characterize this industry (valuations as of April 25th, 2005) :
Market Cap Sales Operating Earnings Price / Sales Price / Operating Earnings P / E Operating Margin Net Margin
Medical Supplies 4.97 25.08 40.50 7.03% 3.12%
Encore Medical Corporation (ENMC) 293.8 108.0 9.2 2.72 31.9 37.42 8.52% 7.27%
Closure Medical Corp. (CLSR) 284.8 35.0 11.9 8.14 23.9 32.56 34.00% 24.99%
OraSure Technologies, Inc (OSUR) 263.3 40.5 -1.2 6.50 -2.96%
AngioDynamics, Inc. (ANGO) 237.7 49.0 5.1 4.85 46.6 54.34 10.41% 8.93%
Schick Technologies, Inc. (SCHK.OB) 237.6 39.4 12.08 6.03 12.7 14.72 30.66% 26.45%
Elbit Medical Imaging Ltd (EMITF) 236.5 125.0 1.1 1.89 20.5 29.51 0.88% 0.61%
CardioDynamics Int'l Corp (CDIC) 227.9 23.5 0.2 9.70 19.7 63.24 0.85% 0.26%
OrthoLogic Corporation (OLGC) 227.3 40.4 4.9 5.63 46.4 12.13% -5.5%
Candela Corporation (CLZR) 216.2 104.0 13.8 2.08 15.7 20.6 13.27% 10.09%
Biolase Technology, Inc. (BLTI) 215.8 49.2 7.4 4.39 29.2 15.04% -0.5%
Possis Medical, Inc. (POSS) 208.4 72.4 18.08 2.88 11.5 19.09 24.97% 15.08%
VNUS Medical Technologies (VNUS) 203.7 21.8 -2.7 9.34 29.2 88.2 -12.3% -22.5%
Medical Action Industries (MDCI) 197.4 127.6 15.9 1.55 12.4 19.29 12.46% 8.02%
Exactech, Inc. (EXAC) 189.8 71.2 9.5 2.67 20.0 27.66 13.34% 9.64%
Cholestech Corporation (CTEC) 183.9 52.4 -2.8 3.51 18.1 26.09 -5.34% -9.12%
Fonar Corporation (FONR) 174.3 71.6 -8.4 2.43 -11.7% -23.5%
Microtek Medical Holdings (MTMD) 170.9 98.6 6.5 1.73 26.3 15.53 6.59% 11.16%
Q-Med, Inc. (QMED) 169.6 12.7 0.3 13.35 2.36% -2.20%
Spectranetics Corporation (SPNC) 158.1 27.8 0.8 5.69 59.2 117.74 2.88% 1.55%
Quidel Corporation (QDEL) 154.3 95.1 11.06 1.62 14.0 11.85 11.63% 13.69%
Cutera, Inc. (CUTR) 152.7 39.1 5.16 3.91 29.6 101.14 13.20% 3.86%
Cardiac Science, Inc. (DFIB) 148.2 62.0 -7.1 2.39 -11.4% -15.7%
Somanetics Corporation (SMTS) 138.6 9.4 0.1 14.74 12.4 17.86 1.06% 0.55%
Quinton Cardiology System (QUIN) 134.2 84.4 -1.5 1.59 22.3 32.08 -1.78% -3.50%
The companies analyzed above are a selection of companies whose activities are somewhat close to the activities of Medify Solutions. The sector’s valuation averages are roughly 5 times sales and 25 times earnings at the present moment. The operating margins and the net margins we have measured are approximately 7% and 3%.
This brings us back to how Medify Solutions is supposed to fit into this sector. It is to be noticed, that Medify’s products fit into the medical supplies sub-sector. Investors appreciate medical supply stocks and thereby the price multiples found are “average to high” by comparison to other industries. Global medical costs rising have always been a good investment argument for many of these companies. Medify not only should benefit from this trend, but in nature, also should be able to achieve much higher margins than the one’s of its sector. We are now viewing Medify Solutions being able to achieve 38% EBIT margins and close to 24% net margins.
These much higher than expected margins obviously deserve explanations. The SPV business model, as explained in the research report written on March 21st, 2005, started with low margins for the first 2 years, in absence of a track record, then to find themselves around 20% at an operating level. Given the early advances, these figures seem to be achievable, especially in sight of Orange taking all the marketing cost in order to rollout the SPV’s.
The E-Learning product’s metrics
The new E-Learning division is going to be just as profitable as the SPV division. Here are the reasons:
1. The addressable market for the e-learning in the NHS is of approximately 430’000’000 US$. This market is articulated as follows: every NHS employee is given a mandatory 30 hours training per year. The employee may absolve this training via an e-learning set of modules. The employee must pay on his own, sometimes via a group of physicians, 30 £ per month (45 US$) for his training. 45 US$ times 12 months are equivalent to 540 US$ per employee per year. By expanding to the 800’000 employees needing such a training, the market size becomes the said 430 million US$.
2. Besides maintenance, improvements to the modules and server hosting charges to Oracle, the costs to delivering the system are very low. Marketing costs can nevertheless be a bit more onerous. An alliance for the marketing will reduce such costs though.
3. We estimate the operating margin of being at 31% (comparison to other equivalent “e-learning” businesses).
4. The weakness to this division is the fact that there is easy access to any competitor. We are forecasting Medify owning 14% of this market share.
Forecast Income Statement
For 2005, we are still quite hesitant on the number of subscribers. Therefore, we expect 8’000 users by December 31st, as only barely 7 months are left in the year. This is a 1% penetration of the NHS professional population. For year 2006, we anticipate a 6% penetration (48’000 users) and a 14% penetration for end 2007 (112’000 users). This should mean sales in excess of 30 million US$ for 2007 for this division only. By adding up the two divisions and their expected results, we anticipate the following profit and loss account for the coming years:
Income Statement 2'004 2005E 2006E 2007E
NET SALES 0.0 3.1 23.2 60.4
Cost of Goods Sold 0.0 -2.4 -8.8 -20.0
GROSS PROFIT 0.0 0.7 14.4 40.4
Personnel Costs 0.0 0.0 0.0 0.0
S,G & A 0.0 -2.3 -6.6 -17.2
EBITDA 0.0 -1.6 7.8 23.2
Fixed Assets Depreciation 0.0 0.0 0.0 0.0
EBIT 0.0 -1.6 7.8 23.2
Interest Income 0.0 0.0 0.0 0.0
Interest Cost 0.0 0.0 0.0 0.0
NET INTEREST INC. / COST 0.0 0.0 0.0 0.0
Taxes 0.0 0.0 -3.0 -8.8
NET PROFIT 0.0 -1.6 4.8 14.4
Free Cash Flow Statement 2'004 2005E 2006E 2007E
CASH FLOW 0.0 -1.6 4.8 14.4
Maintenance Capex 0.0 -0.1 -0.5 -1.2
Increase In N.W.C 0.0 0.0 0.0 0.0
Dividends 0.0 0.0 0.0 0.0
FREE CASH FLOW 0.0 -1.7 4.4 13.2
We initially had the net earnings of Medify at 6.8 million US$. Today, we view them at 14.4 million US$, more than double form our previous forecast. We nevertheless have the impression that we remained conservative in our earnings and that the future might look even better. This long term forecast excludes the temporary ups and down any business will undergo.
TTS Zurich Analyst Price Target set at 3.90 US$
As a summary to the above, we believe that Medify Solutions Inc’s stock should deserve stock valuation multiples equivalent to those of its sector or industry. By extrapolating on the future multiples of the company based on the industry’s growth rate, we give Medify Solutions Inc. the following valuation:
By Price to 2007E Sales: 3.19 * 60.4 million in Sales = 192.7 million US$
By Price to 2007E EBIT: 16.06 * 23.2 million in EBIT = 372.6 million US$
By Price to 2007E Net Profit: 25.94 * 14.4 million in Net Profit = 373.5 million US$
---------------------
Average = 313.9 million US$
By dividing this 313.9 million US$ estimated valuation by the number of shares outstanding (80.656 million), we get a valuation of the shares of Medify Solutions Inc. (MFYS.pk) of 3.90 US$ per share. This valuation is a fair and documented assessment of our present opinion on Medify. As we signaled earlier, this valuation is based upon our realistic forecasts of the company’s future and we remain quite convinced that this future will happen. After all, the company will then be trading only at equivalent levels to its comparatives.
Consensus Stock Price Target
Any investor may also review or contribute to reviewing the consensus price target on MFYS.pk. You may review what other investors and analysts think of Medify Solutions Inc. on the Website of StockTargets consensus stock views (www.stocktargets.com). One can see that the target proposed by TTS Zurich is slightly above consensus target for the stock, as this one is at 3.32 US$.
Key to Success for Medify Solutions Inc.
As we said in the previous report, the key to success for Medify Solutions is permanent innovation. By acquiring Medify e-learning, the company has made very important headway into the NHS and has considerably solidified its position. NHS obliges its professionals to take continuous learning for a specific number of hours during the year. Today, Medify has 2 lucrative contracts with the NHS, in fields they are leaders and / or are a step ahead of any competition.
Disclaimer: TTS Zurich provides information on selected companies that TTS Zurich believes has investment potential, as an independent research firm. TTS Zurich is not a registered investment advisor or broker dealer. This report is provided for information service only and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. TTS Zurich accepts no liability for any loss arising from or investors reliance or use of this report. An investment in MFYS.pk is considered to be highly speculative and should not be considered unless the person can afford a complete loss of investment. TTS Zurich was paid $17,500 USD to effect full research report and news alerts for a 12 months period. TTS Zurich intends to contract other third party IR and PR agencies to expand the scope of the Medify Solutions Inc. story to a wider investor audience. TTS does not trade in this security, nor will it trade in the future in this security. TTS Zurich strives to bring unbiased accurate and timely information to the market place through research. This report contains forward looking statements which involve risks and uncertainties that may cause the actual results to differ from those set forth in the forward looking statements. Information presented in our newsletters contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates," "believes," or that by statements indicating certain actions "may," "could," or "might" occur. READERS SHOULD VERIFY ANY & ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. We encourage our readers to invest carefully and read the investor information available at the websites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. Thank you for taking the time to read through this.
To be on our email list of research reports which are free please visit http://www.ttszurich.com/ or http://www.ttszurich.ch/tts/. If you wish your company to be considered by TTS Zurich, please email us at research@ttszurich.com.
TTS Zurich
14, rue du Rhône, Geneva, CH1204
Switzerland
so it goes up one step at a time, not pinks to nasdaq?
Question
How long of a process is it to get on junior nasdaq?
And does anybody have a guess on when it will happen for mfys?
Andrew said they will qualify after the next 2 pr's...well it has been two so now what? just wondering.
Any info would be apprciated. Thanks
Great post verylong!!!
just put more booze
dudes, I'm from Canada so I doubt you got any of our drinks. I'll have to bring my own, I'd let you guys try it but it's alot stronger up here.( hopefully u guys can handle it. lol)
Theres a website stockwire.com that has been profiling mfys last and this week on their movers and shakers list.
It's not news but it's something to get people to notice it more I guess.
National Holiday in Canada tomorrow.
I don't see that
Friday, news on friday never does what it would on any other day.
Seems like alot of resistance around 87-90.
Seems like a lot of resistance around 87-90
I only glanced at it, but went over it again and I see what your saying. They still don't scare me lol
Quick question,
What overhead costs does medify have, I can think of the obvious but maybe somebody can throw some more out.
Just seems like another company doing the same as medify.
Why are you wondering.
Andrew
Throw us another bone to keep this ball rollin, or this will be like all the other announcements, ( big spike then back down again).
2 pr's...if its about money...big money, high of 1.50 then down with sell off to 1.15
Any Predictions 4 tomorrow
Qiuck Question
I have heard that managment has a hold of many shares in the company and can't sell them for one year. That being said, wouldn't they want the share price to be huge for when that year is up so they can make a bundle?
Appreciate any info.